Key result
Expression of slow skeletal troponin I in adult mice protected against pressure overload, limiting heart size increase to 7% compared to 25% in nontransgenic controls (P<0.05).
Why the study?
Does expression of slow skeletal troponin I protect adult mouse hearts from pressure overload-induced dysfunction and metabolic inefficiency?
Does expression of slow skeletal troponin I protect adult mouse hearts from pressure overload-induced dysfunction and metabolic inefficiency?
Absolute Event Rate: 7% vs 25%
p-value: p=<0.05
Expression of fetal troponin I (ssTnI) in adult mouse hearts protects against pressure overload-induced cardiac decompensation by improving metabolic efficiency through elevated glucose oxidation and reduced anaplerotic flux.
May protect against pressure overload via metabolic efficiency in mice; leaves open translation to human HF therapies.
BACKGROUND: The failing heart displays increased glycolytic flux that is not matched by a commensurate increase in glucose oxidation. This mismatch induces increased anaplerotic flux and inefficient glucose metabolism. We previously found adult transgenic mouse hearts expressing the fetal troponin I isoform, (ssTnI) to be protected from ischemia by increased glycolysis. In this study, we investigated the metabolic response of adult mouse hearts expressing ssTnI to chronic pressure overload. METHODS AND RESULTS: At 2 to 3 months of age, ssTnI mice or their nontransgenic littermates underwent aortic constriction (TAC). TAC induced a 25% increase in nontransgenic heart size but only a 7% increase in ssTnI hearts (P<0.05). Nontransgenic TAC developed diastolic dysfunction (65% increase in E/A ratio), whereas the E/A ratio actually decreased in ssTnI TAC. Isolated perfused hearts from nontransgenic TAC mice showed reduced cardiac function and reduced creatine phosphate:ATP (16% reduction), but ssTnI TAC hearts maintained cardiac function and energy charge. Contrasting nontransgenic TAC, ssTnI TAC significantly increased glucose oxidation at the expense of palmitate oxidation, preventing the increase in anaplerosis observed in nontransgenic TAC hearts. Elevated glucose oxidation was mediated by a reduction in pyruvate dehydrogenase kinase 4 expression, enabling pyruvate dehydrogenase to compete against anaplerotic enzymes for pyruvate carboxylation. CONCLUSIONS: Expression of a single fetal myofilament protein into adulthood in the ssTnI-transgenic mouse heart induced downregulation of the gene expression response for pyruvate dehydrogenase kinase to pressure overload. The consequence of elevated pyruvate oxidation in ssTnI during TAC reduced anaplerotic flux, ameliorating inefficiencies in glucose oxidation, with energetic and functional protection against cardiac decompensation.
No takes yet. Share an insight, caveat, or question.
Carley et al. (2014) studied Pressure overload. Expression of slow skeletal troponin I (ssTnI) vs. Nontransgenic littermates was evaluated on Increase in heart size (p=<0.05). Expression of slow skeletal troponin I in adult mice protected against pressure overload, limiting heart size increase to 7% compared to 25% in nontransgenic controls (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: